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SCIENCE FOR JUDGES VIII:
INTRODUCTION
Margaret A. Berger*
The Journal of Law and Policy is once again publishing
extended versions of presentations made by speakers at a
conference for federal and state judges on science and the law. 1
The conference, which took place at Brooklyn Law School on
November 3 and 4, 2006, was the eighth in a series of Science
for Judges programs funded by the Common Benefit Trust
established in the Silicone Breast Implant Products Liability
Litigation. It was held under the auspices of Brooklyn Law
School’s Center for Health, Science and Public Policy in
collaboration with the Federal Judicial Center, the National
Center for State Courts, and the Committee on Science,
Technology and Law of the National Academies of Science.

*

Suzanne J. and Norman Miles Professor of Law, Brooklyn Law
School. Professor Berger is the Director of the Science for Judges Program.
1
Papers from previous Science for Judges programs can be found at 12
J.L. & POL’Y 1, 1-53 (2003) (papers discussing the practice of epidemiology
and the science produced by administrative agencies); 12 J.L. & POL’Y 485,
485, 485-639 (2004) (papers discussing toxicology and epidemiology); 13
J.L. & POL’Y 1, 1-179 (2005) (papers discussing the integrity of scientific
research and forensic evidence in criminal proceedings); 13 J.L. & POL’Y
499, 499-647 (2005) (papers discussing Agent Orange and human behavior
research); and 14 J.L. & POL’Y 1, 1-209 (2006) (papers discussing risk
assessment dealing with expert proof of causation in toxic tort cases and
issues relevant to the availability of data); 14 J.L. & POL’Y 525, 525-616
(2006) (papers discussing evidence-based medicine); 15 J.L. & POL’Y 1, 1164 (2007) (papers discussing the evidence of causation as well as current
issues and standards of forensic laboratories). All papers are available in
electronic form at http://brooklaw.edu/centers/scienceforjudges/papers.php.
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This time, the program focused on pharmaceutical drugs and
asbestos, two products whose use—past and present—raises
troublesome issues for the American legal system. From a
scientific perspective as well, the questions posed are complex
and costly. In addition to their potent impact on public health
and the litigation process, the issues surrounding
pharmaceuticals and asbestos affect not only the courts but also
congress and administrative agencies. The articles that follow
view the resulting problems in a variety of different contexts that
illustrate the myriad challenges and possible solutions that arise
at the intersection of science and the law. An added bonus is
that two of the papers provide us with a glimpse of how other
legal systems react. Furthermore, these articles are extremely
timely; they deal with current problems some of which may
have received more coverage on the web than in law reviews.
The first article, by Dr. Drummond Rennie, looks at the
pharmaceutical industry from the vantage point of a professor of
medicine and a medical editor, who has worked at the two most
prestigious general medical journals.2 Dr. Rennie tells a
sobering tale of how a changing academic culture led to
enormous conflicts of interest once the Baye-Dole Act’s passage
in 1980, allowed universities to profit from scientific
discoveries. 3 The consequence, according to Dr. Rennie, has
been research misconduct, the biased reporting of results, the
burying of negative results, and the publishing of trials that
ostensibly come from research universities but are actually
produced by the companies sponsoring the studies. He also
discusses changes at the FDA that have made it far more
company-friendly. He offers numerous suggestions for what
must be done in order for the pharmaceutical companies and the
FDA to regain our trust. Dr. Rennie clearly believes that our
present system—as formally constituted and implemented—does
not adequately safeguard the public’s health.
The next article by Professor Catherine Sharkey views the
2

Drummond Rennie, When Evidence Isn’t: Trials, Drug Companies and
the FDA, 15 J.L. & POL’Y 991 (2007).
3
Id. at 997.
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problem of pharmaceuticals from a very different perspective. 4
Even while the FDA was embroiled in a number of controversial
cases, 5 that led to its requesting a review by a committee of the
National Academies’ Institute of Medicine which has now
published a highly critical report, 6 the FDA was issuing a new
rule for labeling prescription drugs. In the preamble to the new
rule the FDA stated its view that the rule preempted competing
state law regulatory and common law claims. 7
Professor Sharkey’s article examines the history of the
preemption doctrine in the products liability realm in general,
considers differences in the response of federal and state courts,
and discusses the abandonment of the regulatory compliance
defense in favor of the federal preemption doctrine. She then
turns to the 2006 preemption claim by the FDA and analyzes the
federal and state cases that have dealt with the issue. She finds,
not surprisingly, that the federal courts have been more
receptive to the FDA’s position. Preemption is obviously a
highly complex issue that implicates federalism concerns as well
as the operation of deference to interpretations by administrative
agencies. Although it is far too soon to know what the ultimate
fate of the preemption defense will be, and its impact on toxic
tort litigation involving pharmaceuticals, it seems safe to predict
that Professor Sharkey’s article will be the starting point for
many discussions of this problem.
Professor Anita Bernstein’s article proceeds on a completely
different track. 8 Although she notes that pharmaceutical
4

Catherine M. Sharkey, Federalism in Action: FDA Regulatory
Preemption in Pharmaceutical Cases In State Versus Federal Courts, J.L. &
POL’Y 1051 (2007).
5
RENNIE, supra note 2, at 1003-006.
6
Institute of Medicine, Committee on the Assessment of the US Drug
Safety System, The Future of Drug Safety: Promoting and Protecting the
Health of the Public (Anita Baciu, et al eds., National Academies Press,
2007).
7
Requirements on Content and Format of Labeling for Human
Prescription Drug and Biological Products, 71 Fed. Reg. 3922, 3934, n. 7
(Jan 24, 2006) (effective date June 30, 2006).
8
Anita Bernstein, Enhancing Drug Effectiveness and Efficacy Through
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companies have on the whole been affected very little by
personal injury litigation, she is willing to assume that such
litigation can cause harm to the drug industry and its customers.
What Professor Bernstein seeks is a means by which prescription
drug liability can play a positive role in improving the practices
of the pharmaceutical industry. She makes the novel suggestion
that courts consider “ineffectiveness” as an actionable injury
instead of tying liability solely to a lack of safety. In Part I of
her article she explores the meaning of effectiveness, including
the difference between effectiveness and efficacy. Part II
examines the harms caused to consumers by ineffective drugs
that do not live up to promises on a label, and in Part III
Professor Bernstein makes specific suggestions for modest first
steps that courts could take when manufacturers make false
promises. Her thesis promotes a fresh scrutiny of the
pharmaceutical industry to determine whether the current system
is in the public’s best interest, and asks that we reconsider the
role of the tort system.
The last article about pharmaceuticals by Robert Nakagawa,
a member of the British Columbia Ministry of Health, discusses
measures Canada has taken to reduce the price of prescription
drugs. 9 Each provincial government determines for which drugs
they will provide payment. Safety and efficacy assessments enter
into these determinations which British Columbia reaches by
considering information generated by its extensive database
which currently includes all prescriptions dispensed within
province’s pharmacies since 1995. The extensive database also
operates to detect fraud and to identify emerging problems, such
as harmful interactions caused by taking more than one drug.
Many of the problems discussed in the preceding articles on
pharmaceuticals could undoubtedly be avoided in the United
States if more information were available on how the
prescription drugs on the American market actually work.
The articles on asbestos are equally rich. It may surprise
Personal Injury Litigation, 15 J.L. & POL’Y 1051 (2007).
9
Robert S. Nakagawa, Prescription Drug Systems and Price Control in
Canada, 15 J.L. & POL’Y 1103 (2007).
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some that more than fifty years after exposure to asbestos fibers
was linked to cancers of the respiratory tract, and more than
thirty years after asbestos litigation began, unresolved questions
remained about asbestos and the causation of non-respiratory
cancers. Dr. Jonathan Samet writes about the Institute of
Medicine Committee he chaired which Congress charged with
carrying out a study on the association of asbestos with
colorectal, laryngeal, oropharyngeal, stomach, and esophageal
cancers. 10 Dr. Samet’s discussion of the methodology used by
the Committee, the reasons for uncertainties that remain, the
classification system adopted by the Committee, and the
Committee’s findings will be of interest not only to those who
deal with asbestos, but to all concerned with issues of causation
from the legal or scientific perspective. As causation is the
crucial problem in virtually all toxic tort litigation, this essay
should attract many readers in a variety of disciplines.
The next article by Patrick Hanlon, which discusses the
attempt to handle asbestos claims through federal legislation, 11 is
related to the previous article by Dr. Samet. Congress had
commissioned the Institute of Medicine study, because the
information sought was needed to implement a congressional
compensation scheme. Ultimately, as Mr. Hanlon relates, the
proposed FAIR Act failed to pass. His explanation of the
provisions in the bill, the numerous complex scientific questions
that had to be addressed, and the policy issues that could not be
resolved make fascinating reading. This is an article about
science, law and politics. The descriptions of the various
constituencies that had a stake in the bill and their reactions
suggest that legislation may never be a viable option for
reforming toxic tort litigation. In that case, of course, most
decision-making will be left to the courts. Fortunately, the
number of new asbestos claims has decreased dramatically for

10

Jonathan M. Samet, Asbestos and Causation of Non-Respiratory
Cancers: Evaluation by the Institute of Medicine, 15 J.L. & POL’Y 1117
(2007).
11
Patrick M. Hanlon, Federal Asbestos Legislation: Wrestling with the
Medical Issues, 15 J.L. & POL’Y 1171 (2007).
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reasons also explored by Mr. Hanlon.
David Michaels and Celeste Monforton examine instances in
which the scientific literature on asbestos has been skewed by
litigation generated science. 12 Looking almost exclusively at the
literature on auto mechanics’ exposure to asbestos in friction
products, Michaels and Monforton could find only one new
epidemiological study on disease risk for auto mechanics in the
ten years following the Occupational Safety and Health
Administration’s
(“OSHA”)
final
asbestos
standard. 13
Nevertheless, 39 papers have been published that do not contain
new scientific data. Of these, the authors identified 26 as
litigation-generated papers which offer literature reviews and
reanalyze in a manner that would be useful for litigation.
Michaels and Monforton conclude that the result is that
whichever side pays more has more papers published. What
looks like a consensus in the scientific community is instead “an
artifact of sponsorship.” 14 At least as troubling is Michaels’ and
Montforton’s charge that government agencies like the
Environmental Protection Agency (“EPA”) and OSHA have
been pressured to remove valuable information from publications
that linked asbestos exposure to disease in auto mechanics.
The last paper on asbestos litigation in New South Wales,
Australia, was submitted by Judge Lawrence O’Meally, the
President of the Dust Diseases Tribunal of New South Wales. 15
Australia apparently has an incidence of malignant
mesothelioma—an asbestos signature disease—that is higher than
that of any other country. Until the Tribunal was established,
some claimants died before their claims were heard in court.
Since 1989, these claims are now handled on an expedited basis
12

David Michaels & Celeste Monforton, How Litigations Shapes the
Scientific Literature: Asbestos and Disease Among Auto Mechanics, 15 J.L.
& POL’Y 1127 (2007).
13
The reasons for why new research has not been done are explored id.
at 1157-161.
14
Id. at 1166.
15
Hon. John Lawrence O’Meally, Asbestos Litigation In New South
Wales, J.L. & POL’Y 1209 (2007).
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before the Tribunal, which is a parallel court system in which all
cases are tried before a judge. All cases are subject to
compulsory mediation. Judge O’Meally’s paper examines some
of the other provisions of the Act. He makes the astonishing
statement that in some cases less than four hours elapse between
the filing of a statement of claim and the conclusion of the
case. 16
The articles based on the eighth Science for Judges program
illuminate how difficult it is to resolve issues relating to
pharmaceuticals and asbestos. On top of the ordinary
complexities posed when science and the law intersect are
problems such as the conflicts of interest and unethical behavior
attributable to the enormous sums at stake, political pressures,
unsettled issues about federalism, and uncertainties about the
appropriate role of administrative agencies and congress. New
and better solutions are definitely needed, but these articles spell
out the enormous obstacles that have to be overcome.

16

Id. at 1215.

